|
業務類別
|
Biotechnology |
|
業務概覽
|
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections. |
| 公司地址
| One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 800 466-6059 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.aligos.com |
| 員工數量
| 82 |
| Dr. Lawrence M. Blatt,PhD |
Chairman of the Board, President and Chief Executive Officer |
美元 651.72K |
29/04/2026 |
| Mr. Nikhil Aneja |
Principal Accounting Officer |
-- |
04/02/2026 |
| Ms. Lesley Ann Calhoun |
Chief Operating Officer, Executive Vice President and Chief Financial Officer |
美元 502.00K |
04/02/2026 |
| Dr. Julian A. Symons, D.Phil. |
Executive Vice President and Chief Scientific Officer |
美元 492.76K |
29/04/2026 |
|
|
| Dr. Lawrence M. Blatt,PhD |
Chairman of the Board, President and Chief Executive Officer |
29/04/2026 |
| Ms. Margarita Chavez, J.D. |
Independent Director |
29/04/2026 |
| Mr. James Scopa |
Independent Director |
29/04/2026 |
| Dr. Bridget A. Martell, M.D. |
Independent Director |
29/04/2026 |
| Ms. Carole L. Nuechterlein, J.D. |
Lead Independent Director |
29/04/2026 |
| Dr. Heather Elizabeth Preston, M.D. |
Independent Director |
29/04/2026 |
| Dr. K. Peter Hirth, PhD |
Independent Director |
29/04/2026 |
|
|
|
|
